Eupraxia Pharmaceuticals Inc.

EPRX

CA29842P1053

Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 12:35:39 2024-07-16 EDT			5-day change	1st Jan Change
3.7 ^CAD	+0.54%		+2.49%	-31.10%

07-03	Eupraxia Pharmaceuticals Inc. Brief: Says CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024	MT
06-05	Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	MT

Eupraxia Pharmaceuticals Inc. Elects Richard M. Glickman to Board of Directors

December 03, 2021 at 02:15 pm

Eupraxia Pharmaceuticals Inc. at its Annual General Meeting of Shareholders held on December 3, 2021 elected Richard M. Glickman to board of directors.

Latest news about Eupraxia Pharmaceuticals Inc.

Eupraxia Pharmaceuticals Inc. Brief: Says CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024	07-03	MT
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024	06-05	MT
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	05-23	MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	05-23	MT
Sector Update: Health Care Stocks Lower Premarket Wednesday	05-22	MT
Sector Update: Health Care	05-22	MT
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial	05-22	CI
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours	05-21	MT
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%	05-21	MT
Eupraxia Pharmaceuticals Up 70% In US After Hours As Announces New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	05-21	MT
Eupraxia Pharmaceuticals Inc. Brief: Announcing New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis	05-21	MT
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis	05-21	CI
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024	05-14	MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
Eupraxia Pharmaceuticals Forms Gastrointestinal Clinical Advisory Board	05-02	MT
Top Premarket Decliners	04-08	MT
Eupraxia Pharmaceuticals Inc.(NasdaqCM:EPRX) added to NASDAQ Composite Index	04-07	CI
Eupraxia Pharmaceuticals Inc. Brief: Begins Trading on Nasdaq Today	04-05	MT
Eupraxia Pharmaceuticals Inc. Brief: Says to Begin Trading on Nasdaq on April 5, 2024	04-03	MT
Eupraxia Pharmaceuticals Inc. Brief: Says incurred a net loss of US$10.6 million for Q4, versus $7.8 million for the three months ended December 31, 2022	04-01	MT
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-01	CI
Eupraxia Pharmaceuticals Completes Overnight Marketed Offering	03-15	MT
Toronto Stocks Edge Forward; Shares of Altius Minerals Rise on 4Q Revenue Beat	03-12	DJ
Eupraxia Pharmaceuticals Prices Overnight Marketed Offering of C$30 Million	03-12	MT
Eupraxia Pharmaceuticals Seeking C$30 Million in an Overnight Marketed Share Offering	03-11	MT

Chart Eupraxia Pharmaceuticals Inc.

Duration

Period

More charts

Eupraxia Pharmaceuticals Inc. is a Canada-based clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release alternatives to approved drugs. The Companyâs principal business is the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product candidate, EP-104IAR, is designed to meet the unmet medical need and market demand for long-lasting pain relief for knee osteoarthritis (OA). The primary active ingredient of the EP-104 products consists of a solid core of fluticasone propionate (FP) coated with an outer layer of polyvinyl alcohol (PVA). Its lead product candidate is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms and is used corticosteroid with systemic safety record. EP-104 is in Phase Ib/IIa clinical development.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.68 CAD

Average target price

15.13 CAD

Spread / Average Target

+311.23%

Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
EUPRAXIA PHARMACEUTICALS INC.	-31.10%	95.94M
MODERNA, INC.	+26.79%	46.56B
LONZA GROUP AG	+45.38%	41.67B
IQVIA HOLDINGS INC.	+0.07%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+32.71%	32.4B
ICON PUBLIC LIMITED COMPANY	+20.82%	28.18B
CELLTRION, INC.	-6.35%	28.1B
UNITED THERAPEUTICS CORPORATION	+48.96%	14.52B
MEDPACE HOLDINGS, INC.	+47.88%	13.74B
BIO-TECHNE CORPORATION	+3.24%	12.17B

Other Biotechnology & Medical Research